Abstract 196P
Background
High-grade serous ovarian carcinoma (HGSOC) remains the deadliest gynecologic malignancy, primarily due to its asymptomatic nature in the early-stages and the complex, poorly understood mechanisms driving its progression.
Methods
In this study, we employed single-cell RNA-seq analysis to delve deeper into early-stage of HGSOC, uncovering a previously underappreciated dominant infiltration and heterogeneity of regulatory T (Treg) cells.
Results
Within the HGSOC lesions, we detected CD4 regulatory T cells (Tregs) displaying diverse transcriptomic profiles indicative of their naïve, effector, proliferating, and destabilized states. The presence of Tregs was associated with an immunosuppressive tumor microenvironment, featured by CD4 Th2 cells, exhausted CD8 T cells, lacking cytotoxicity NK cells, and tumor-associated macrophages (TAMs). Cell-to-cell communication analysis predicted Treg-mediated inhibition of immune responses and reciprocal interactions with tumor cells promoting Treg activation. Trajectory analysis revealed two Treg differentiation paths, both leading to immunosuppressive FOXP3high and FOXP3+ Treg profiles. Notably, while the trajectory of FOXP3high profile converges with proliferating Tregs, the second path of cytotoxic FOXP3+ Tregs aligned with FOXP3- ex-Tregs, distinguished by an anti-tumor CXCL13+IFNG+ transcriptomic profile.
Conclusions
Therefore, despite the immunosuppressive environment, we identified the counteracting antitumor activity of Tregs, highlighting the potential of manipulating Treg cell fate as for therapeutic strategies.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session